Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

The Cancer Vaccine Consortium of the Sabin Vaccine Institute (CVC/SVI) is conducting an ongoing large-scale immune monitoring harmonization program through its members and affiliated associations. This effort was brought to life as an external validation program by conducting an international Elispot proficiency panel with 36 laboratories in 2005, and was followed by a second panel with 29 participating laboratories in 2006 allowing for application of learnings from the first panel. Critical protocol choices, as well as standardization and validation practices among laboratories were assessed through detailed surveys. Although panel participants had to follow general guidelines in order to allow comparison of results, each laboratory was able to use its own protocols, materials and reagents. The second panel recorded an overall significantly improved performance, as measured by the ability to detect all predefined responses correctly. Protocol choices and laboratory practices, which can have a dramatic effect on the overall assay outcome, were identified and lead to the following recommendations: (A) Establish a laboratory SOP for Elispot testing procedures including (A1) a counting method for apoptotic cells for determining adequate cell dilution for plating, and (A2) overnight rest of cells prior to plating and incubation, (B) Use only pre-tested serum optimized for low background: high signal ratio, (C) Establish a laboratory SOP for plate reading including (C1) human auditing during the reading process and (C2) adequate adjustments for technical artifacts, and (D) Only allow trained personnel, which is certified per laboratory SOPs to conduct assays. Recommendations described under (A) were found to make a statistically significant difference in assay performance, while the remaining recommendations are based on practical experiences confirmed by the panel results, which could not be statistically tested. These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels.

[1]  H. Lyerly,et al.  Surrogate markers of response to cancer immunotherapy , 2001, Expert opinion on biological therapy.

[2]  Sylvia Janetzki,et al.  Automation of the Elispot Technique: Past, Present, and Future , 2004 .

[3]  Devan Mehrotra,et al.  Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay , 2007, Journal of acquired immune deficiency syndromes.

[4]  Xu Liu,et al.  Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus , 2001, Clinical Diagnostic Laboratory Immunology.

[5]  M. Hudgens,et al.  Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. , 2003, The Journal of infectious diseases.

[6]  E. Thiel,et al.  Immunological monitoring of cancer vaccine therapy , 2004, Expert opinion on biological therapy.

[7]  E. Walker,et al.  MONITORING IMMUNE RESPONSES IN CANCER PATIENTS RECEIVING TUMOR VACCINES , 2003, International reviews of immunology.

[8]  J. Lathey.  Preliminary steps toward validating a clinical bioassay: A case study of the ELIspot assay , 2003 .

[9]  T. Whiteside.  Immunologic Monitoring of Clinical Trials in Patients with Cancer: Technology Versus Common Sense , 2000, Immunological investigations.

[10]  C. Pitcher,et al.  Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. , 2001, Journal of immunological methods.

[11]  Sylvia Janetzki,et al.  Measurement of cytokine release at the single cell level using the ELISPOT assay. , 2006, Methods.

[12]  A. McMichael,et al.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. , 2002, AIDS research and human retroviruses.

[13]  J. Gaddum,et al.  United States Pharmacopeia , 1955, Nature.

[14]  C. Gouttefangeas,et al.  Toward the harmonization of immune monitoring in clinical trials: Quo vadis? , 2007, Cancer Immunology, Immunotherapy.

[15]  J. W. Findlay,et al.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.

[16]  M. Atkins,et al.  Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy , 2002, Journal of immunotherapy.

[17]  Sylvia Janetzki,et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.

[18]  S Janetzki,et al.  Evaluation of Elispot assays: influence of method and operator on variability of results. , 2004, Journal of immunological methods.

[19]  A. Samri,et al.  Evaluation of the Interlaboratory Concordance in Quantification of Human Immunodeficiency Virus-Specific T Cells with a Gamma Interferon Enzyme-Linked Immunospot Assay , 2006, Clinical and Vaccine Immunology.

[20]  H. Maecker.  The Role of Immune Monitoring in Evaluating Cancer Immunotherapy , 2006 .

[21]  D. Niedzwiecki,et al.  Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood: A Comparison of Peptide MHC Tetramer, ELISpot, and Intracellular Cytokine Analysis , 2005, Journal of immunotherapy.

[22]  A. Eggermont,et al.  A clinical development paradigm for cancer vaccines and related biologics. , 2007, Journal of immunotherapy.

[23]  T. Whiteside,et al.  Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines , 2000, Clinical Diagnostic Laboratory Immunology.

[24]  A. Eggermont,et al.  Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.

[25]  I. Stănescu,et al.  Validation overview of bio-analytical methods , 2005, Gene Therapy.

[26]  M. Caulfield,et al.  Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions , 2007, Clinical and Vaccine Immunology.

[27]  Guido Ferrari,et al.  Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. , 2005, AIDS research and human retroviruses.

[28]  D. Mehrotra,et al.  Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. , 2007, AIDS research and human retroviruses.

[29]  R. Koup,et al.  Automating Procedures for Processing, Cryopreservation, Storage, and Manipulation of Human Peripheral Blood Mononuclear Cells , 2004 .

[30]  Sylvia Janetzki,et al.  Standardization and validation issues of the ELISPOT assay. , 2005, Methods in molecular biology.

[31]  A. Mackensen,et al.  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.